Solange Peters, MD, PhD


Biomarkers Employed in CheckMate 739 for Patients With MPM

Solange Peters, MD, PhD, discusses the biomarkers for immunotherapy used in the phase 3 CheckMate 743 trial.

Thomas Bachelot, MD, PhD


Best Therapies for HER2+ Breast Cancer Are Also Best for Brain Metastases

Thomas Bachelot, MD, PhD, discusses therapies available for patients with HER2-positive breast cancer and brain metastases.

Ana Velázquez Mañana, MD, MSc


Key Takeaways Regarding Biomarker Testing for mNSCLC

Closing thoughts from a panel of NSCLC experts, with an emphasis on improving access to and utilization of biomarker testing for patients with the disease.

Aakash Desai, MBBS, MPH


COVID-19 and Its Impact on Oncology Clinical Trials

Coronavirus disease 2019 has disrupted oncologic care across the spectrum of cancer screening, diagnosis, and management.

Christopher Melani, MD


About the ViPOR Regimen in Aggressive Lymphomas

Christopher J. Melani, MD, discusses the combination regimen from the ViPOR study evaluating patients with aggressive lymphomas.

Ashley Gallagher


Low Receipt of ACR-Recommended Follow-Care Discovered Among Patients With Lung Cancer

According to a prospective study of lung cancer screening examinations conducted over a 5-year period, there is low adherence to guidelines recommending follow-up radiologic imaging or diagnostic procedures in patient with lung cancer.

Jonathan W. Goldman, MD


Strategies for Managing Adverse Events of Osimertinib for EGFR+ NSCLC

Jonathan W. Goldman, MD, discusses management of the most common adverse events associated with osimertinib in patients with non–small cell lung cancer.

Sarah A. Alwardt, PhD


Underused Next-Generation Sequence Testing Revealed in MYLUNG Consortium Study

Results from the first phase of the broad, collaborative MYLUNG research study in lung cancer provide a close-up look at current biomarker testing rates and turnaround times for patients treated in community practices within The US Oncology Network.

Binbin Zheng-Lin, MD, MSc


Pancreatic Cancer Awareness Month: Novel Targeted Therapy in PDAC

The landscape for patients with pancreatic ductal adenocarcinoma has shifted due to novel targeted therapies that are opening new options for patients.

Sam Chang, MD, MBA


Methods and Design of the QUILT 3032 Study in NMIBC

Sam S. Chang, MD, MBA, discusses the methods and design of the QUILT 3032 study.

John P. Diaz, MD


Discussing the Advantages of Gynecologic Oncology Meetings

John P. Diaz, MD, discusses how meetings on gynecologic oncology provide advantages for everyday physicians to keep track of the latest updates on the treatment landscape.

Declan Murphy, MD


Exploring PSMA Therapies in Prostate Cancer

Declan Murphy, MD, discusses the current interest in using PSMA, following the FDA’s approval of Gallium 68 PSMA-11, which marks the first ever drug for PET imaging of PSMA-positive lesions in men with prostate cancer.

Siddhartha Mukherjee, MD


Gene Editing Used to Enhance AML Antigen Targeting for CAR T-Cell Therapy

Siddhartha Mukherjee, MD, discusses potential means of targeting chimeric antigen receptor T-cell therapy for patients with acute myeloid leukemia.

Russ Conroy


CheckMate 9ER Trial of Nivolumab/Cabozantinib Continues to Elicit Clinical Benefit in RCC

Nivolumab and sunitinib combined in the first-line treatment continues to maintain benefit for patients with advanced or metastatic renal cell carcinoma.

Giuseppe Giaccone, MD, PhD


Overview of MET Amplification and MET Exon 14 Skipping Mutations in NSCLC

Giuseppe Giaccone, MD, PhD, discusses alterations in the MET gene that can be oncogenic drivers in patients with non–small cell lung cancer.

Jonah Feldman


CRS Associated With Coagulation Disorders in CAR T-Cell Therapy in Multiple Myeloma

A comprehensive analysis of the phase 1 LEGEND-2 study shows a correlation between cytokine release syndrome and coagulation disorders inpatient with multiple myeloma treated with CAR T cells.

Colleen Moretti


Darolutamide Plus ADT, Docetaxel Improves OS in Patients with mHSPC, Regardless of Disease Volume and Risk

The triplet therapy should become the new standard of care for this patient population, according to recent data.

David Qualls, MD


How Will New Immunotherapies Fit Into the Treatment Landscape of Follicular Lymphoma?

Future directions for follicular lymphoma treatments include potential use earlier in treatment or as combination therapy, identifying patients who will benefit most from treatment, and minimizing the costs of therapy while maximizing accessibility.

Pankit Vachhani, MD


Myeloproliferative Neoplasms: Future Directions in Care

Closing out their discussion on the management of myeloproliferative neoplasms, Rami S. Komrokji, MD, and Pankit Vachhani, MD, look toward the future treatment paradigm.

Steven Albelda, MD


CAR T-Cell Use Generates Hope in Solid Tumors

Steven M. Albelda, MD, discusses what he expects the future of chimeric antigen receptor T-cell use in solid tumors to look like.

Pavlos Msaouel, MD, PhD


Treatments Differ in Rare Versus More Common Kidney Cancers

Pavlos Msaouel, MD, PhD, discusses how the treatments and outcomes differ between patients with the rarer disease of renal medullary carcinoma than the more common renal cell carcinoma.

Dhwani Mehta, MS


Incorporating Biomarker Testing in Community Cancer Clinics: A Real-World Pilot Study

Although there is tremendous excitement about boundaries of science stretching beyond human imagination, realizing the real-world impact of scientific advancement on the health outcomes of patients provides a reality check on how far we still must go.

Smruthy Sivakumar, PhD


Exploring Underrepresentation in Clinical Trials of Prostate Cancer

Smruthy Sivakumar, PhD, discusses a large-scale analysis of comprehensive genomic profiling utilization and ancestral characterization of the genomic landscape in patients with advanced prostate cancer.

Benjamin Saylor


Antitumor Activity Associated With Pembrolizumab in BCG-Unresponsive Papillary NMIBC

Pembrolizumab generated antitumor activity in patients with BCG-unresponsive, papillary high-risk non–muscle-invasive bladder cancer, according to cohort B of the phase 2 Keynote-057 trial.

Salvatore Siena, MD


Trastuzumab Deruxtecan Demonstrates Efficacy for mCRC in DESTINY-CRC01

Salvatore Siena, MD, discusses the efficacy of the phase 2 DESTINY-CRC01 trial of trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer who have progressed on 2 or more treatments in this setting.

Mark Markowski, MD, PhD


Favorable Safety Profile Seen With Sabizabulin in mCRPC

Mark Markowski, MD, PhD, discusses the results of a phase 1b/2 study examining treatment with sabizabulin in patients with metastatic castration-resistant prostate cancer.

Dennis J. Slamon, MD, PhD


Longer Follow-Up of MONALEESA-3 Shows Subgroup Efficacy and Safety

Dennis J. Slamon, MD, PhD, discusses the subgroup benefits and safety profile of ribociclib plus fulvestrant in patients with hormone receptor-positive, HER2-negative advanced breast cancer.

Mounzer Agha, MD


Exploring the Key Takeaways from the CARTITUDE-2 Trial in Multiple Myeloma

Mounzer Agha, MD, discusses the phase 2 CARTITUDE-2 trial looking at ciltacabtagene autoleucel in patients with multiple myeloma.